Abstract：
OBJECTIVE: Acute kidney injury (AKI) is a common complication in patients with sepsis, and early detection and timely treatment are crucial. This article aims to explore the clinical role of microRNA-155 (miR-155) in early diagnosis and prognosis evaluation of septic patients with acute kidney injury.
METHODS: We collected the blood samples of septic patients and measured the relative expression of serum miR-155 by RT-qPCR, and drew the receiver operating characteristic (ROC) curves to evaluate its early diagnosis for septic AKI.
RESULTS: The relative expression of miR-155 in the septic AKI was significantly higher than that in the septic non-AKI, and increased with the aggravation of renal function damage. The ROC curve of miR-155 for the diagnosis of septic AKI was 1.91 (95% CI: 1.61-2.19). When the optimal cut-off value of miR-155 expression was 2.37, its sensitivity for diagnosing septic AKI was 91.12% (95% CI: 80.41-95.07%), and its specificity was 84.52% (95% CI: 71.74-89.36%). Furthermore, the severity of kidney injury, SOFA score, APACHE II score and miR-155 were the risk factors affecting the prognosis of septic patients with AKI.
CONCLUSIONS: Serum miR-155 can be used as a novel biomarker for the early diagnosis of septic AKI, and also has important clinical value in the prognosis evaluation of septic patients with AKI.
METHODS: We collected the blood samples of septic patients and measured the relative expression of serum miR-155 by RT-qPCR, and drew the receiver operating characteristic (ROC) curves to evaluate its early diagnosis for septic AKI.
RESULTS: The relative expression of miR-155 in the septic AKI was significantly higher than that in the septic non-AKI, and increased with the aggravation of renal function damage. The ROC curve of miR-155 for the diagnosis of septic AKI was 1.91 (95% CI: 1.61-2.19). When the optimal cut-off value of miR-155 expression was 2.37, its sensitivity for diagnosing septic AKI was 91.12% (95% CI: 80.41-95.07%), and its specificity was 84.52% (95% CI: 71.74-89.36%). Furthermore, the severity of kidney injury, SOFA score, APACHE II score and miR-155 were the risk factors affecting the prognosis of septic patients with AKI.
CONCLUSIONS: Serum miR-155 can be used as a novel biomarker for the early diagnosis of septic AKI, and also has important clinical value in the prognosis evaluation of septic patients with AKI.
摘要：
目的：急性肾损伤（AKI）是脓毒症患者常见的并发症，早期发现和及时治疗至关重要。本文旨在探讨微小RNA-155(miR-155)在脓毒症急性肾损伤患者早期诊断及预后评估中的临床作用。
方法：我们收集脓毒症患者的血样，通过RT-qPCR检测血清miR-155的相对表达，并绘制受试者工作特征（ROC）曲线，以评估其对感染性AKI的早期诊断。
结果：脓毒症AKI中miR-155的相对表达量明显高于非脓毒症AKI。并随着肾功能损害的加重而加重。miR-155诊断脓毒症AKI的ROC曲线为1.91(95%CI:1.61-2.19)。当miR-155表达的最佳截断值为2.37时，其诊断感染性AKI的敏感性为91.12%(95%CI:80.41-95.07%)，特异性为84.52%(95%CI:71.74-89.36%)。此外，肾损伤的严重程度，SOFA得分,APACHEⅡ评分和miR-155是影响脓毒症AKI患者预后的危险因素。
结论：血清miR-155可作为感染性AKI早期诊断的新生物标志物。对脓毒症合并AKI患者的预后评估也具有重要的临床价值。
方法：我们收集脓毒症患者的血样，通过RT-qPCR检测血清miR-155的相对表达，并绘制受试者工作特征（ROC）曲线，以评估其对感染性AKI的早期诊断。
结果：脓毒症AKI中miR-155的相对表达量明显高于非脓毒症AKI。并随着肾功能损害的加重而加重。miR-155诊断脓毒症AKI的ROC曲线为1.91(95%CI:1.61-2.19)。当miR-155表达的最佳截断值为2.37时，其诊断感染性AKI的敏感性为91.12%(95%CI:80.41-95.07%)，特异性为84.52%(95%CI:71.74-89.36%)。此外，肾损伤的严重程度，SOFA得分,APACHEⅡ评分和miR-155是影响脓毒症AKI患者预后的危险因素。
结论：血清miR-155可作为感染性AKI早期诊断的新生物标志物。对脓毒症合并AKI患者的预后评估也具有重要的临床价值。
